Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

RLAY

Live52w high -28.2%

Annual Quarterly

Core line items from RLAY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: RELAY THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$214.20K	$3.00M	$15.36M	$8.36M	$8.36M
Operating Income	Not available	$-78.59M	$-302.74M	$-242.11M	$-161.72M
Net Income	Not available	$-73.29M	$-276.48M	$-221.59M	$-70.38M
EPS (Diluted)	$-0.40	$-0.41	$-1.61	$-1.30	$-0.87
Total Assets	Not available	$699.61M	$621.33M	$670.00M	$728.84M
Total Liabilities	Not available	$57.43M	$54.27M	$62.29M	$63.18M
Cash & Equivalents	Not available	$204.59M	$84.02M	$91.56M	$113.94M
Free Cash Flow OCF − CapEx	Not available	Not available	$-235.87M	$-191.00M	$-128.88M
Shares Outstanding	Not available	189.21M	173.87M	172.63M	171.69M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from RLAY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -28.2%

Entity: RELAY THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$214.20K	$3.00M	$15.36M	$8.36M	$8.36M
Operating Income	Not available	$-78.59M	$-302.74M	$-242.11M	$-161.72M
Net Income	Not available	$-73.29M	$-276.48M	$-221.59M	$-70.38M
EPS (Diluted)	$-0.40	$-0.41	$-1.61	$-1.30	$-0.87
Total Assets	Not available	$699.61M	$621.33M	$670.00M	$728.84M
Total Liabilities	Not available	$57.43M	$54.27M	$62.29M	$63.18M
Cash & Equivalents	Not available	$204.59M	$84.02M	$91.56M	$113.94M
Free Cash Flow OCF − CapEx	Not available	Not available	$-235.87M	$-191.00M	$-128.88M
Shares Outstanding	Not available	189.21M	173.87M	172.63M	171.69M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.